Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons
This chapter (2017) reviews the effects of serotonergic psychedelics on cortical layer V pyramidal neurons.
Authors
- Marek, G. J.
Published
Abstract
Recordings made from layer V (L5) pyramidal cells of the prefrontal cortex (PFC) and neocortex in rodent slice preparations have shown that serotonin (5-hydroxytryptamine, 5-HT) and serotonergic hallucinogens induce an increase in the frequency of spontaneous excitatory postsynaptic currents (EPSCs) in the apical dendritic field by activating 5-HT2A receptors. Serotonergic hallucinogens induce late EPSCs and increase recurrent network activity when subcortical or mid-cortical regions are stimulated at low frequencies (e.g., 0.1 Hz). A range of agonists or positive allosteric modulators (PAMs) for mostly Gi/o-coupled receptors, including metabotropic glutamate2 (mGlu2), adenosine A1, or μ-opioid receptors, suppress these effects of 5-HT2A receptor stimulation. Furthermore, a range of mostly Gq/11-coupled receptors (including orexin2 [OX2]; α1-adrenergic, and mGlu5 receptors) similarly induce glutamate (Glu) release onto L5 pyramidal cells. Evidence implicates a number of brain regions in mediating these effects of serotonergic hallucinogens and Gq/11-coupled receptors including the midline and intralaminar thalamic nuclei, claustrum, and neurons in deep PFC. These effects on 5-HT2A receptors and related GPCRs appear to play a major role in the behavioral effects of serotonergic hallucinogens, such as head twitches in rodents and higher order behaviors such as rodent lever pressing on the differential-reinforcement-of-low rate 72-s (DRL 72-s) schedule. This implies that the effects of 5-HT2A receptor activation on the activity of L5 pyramidal cells may be responsible for mediating a range of behaviors linked to limbic circuitry with connectivity between the PFC, striatum, thalamus, claustrum, striatum, amygdala, and the hippocampal formation.
Research Summary of 'Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons'
Introduction
Marek frames this chapter as an integration of decades of electrophysiological, pharmacological, lesion, behavioural and clinical evidence linking serotonergic hallucinogens to glutamatergic signalling in the prefrontal cortex (PFC) and neocortex. Earlier work established that LSD, mescaline and psilocybin share potent agonism at 5-HT2A receptors and that activation of these receptors can produce psychotomimetic effects. Over time, however, it became clear that simple 5-HT2A blockade does not fully account for the clinical picture of psychosis and that interactions with glutamate transmission, especially onto layer V (L5) pyramidal neurons, offer a richer mechanistic account relevant to perception, cognition, mood and potential therapeutics. This review sets out to synthesise findings showing that 5-HT2A receptor activation evokes glutamate (Glu) release onto the apical dendritic field of L5 pyramidal cells, producing spontaneous and late excitatory postsynaptic currents (EPSCs) and recurrent network activity. Marek aims to connect cellular and circuit-level mechanisms (including the likely involvement of midline/intralaminar thalamic nuclei, claustrum and deep PFC neurons) to behavioural readouts in rodents and to clinical observations, with attention to the modulatory roles of many G-protein-coupled receptors (GPCRs) that either enhance or suppress this Glu release.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typemeta
- Journal
- Topic
- APA Citation
Marek, G. J. (2017). Interactions of hallucinogens with the glutamatergic system: permissive network effects mediated through cortical layer V pyramidal neurons. Current Topics in Behavioral Neurosciences, 107-135. https://doi.org/10.1007/7854_2017_480
References (2)
Papers cited by this study that are also in Blossom
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Cited By (17)
Papers in Blossom that reference this study
Bradley, E. R., Sakai, K., Fernandes-Osterhold, G. et al. · Neuropsychopharmacology (2025)
Buchborn, T., Kettner, H., Kartner, L. et al. · Frontiers in Neuroscience (2023)
Tiwari, P., Sayali, C., Doss, M. K. et al. · Psychedelic Medicine (2023)
Ort, A., Smallridge, J. W., Sarasso, S. et al. · iScience (2023)
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)
Avram, M., Rogg, H., Korda, A. et al. · Frontiers in Psychiatry (2021)
Dos Santos, R. G., Hallak, J. E., Baker, G. et al. · Journal of Psychopharmacology (2021)
Thomas, C. W., Blanco-Duque, C., Breant, B. et al. · Translational Psychiatry (2021)
Bouso, J. C., Ona, G., Dos Santos, R. G. et al. · Advances in Experimental Medicine and Biology (2021)
Show all 17 papersShow fewer
Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)
Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Dos Santos, R. G., Hallak, J. E. · Neuroscience and Biobehavioral Reviews (2020)
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Galvão-Coelho, N. L., de Almeida, R. N., de Menezes Galvão, A. C. et al. · Frontiers in Psychology (2019)
Dos Santos, R. G., Bouso, J. C., Hallak, J. E. · Expert Review of Clinical Pharmacology (2018)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.